The NMDA-NR1 receptor subunit and the mu-opioid receptor are expressed in somatodendritic compartments of central nucleus of the amygdala neurons projecting to the bed nucleus of the stria terminalis.
The pathway between the central nucleus of the amygdala (CeA) and the bed nucleus of the stria terminalis (BNST) is emerging as a critical mediator of stress-related affective processes. Evidence also indicates that exposure to drugs of abuse, like opioids, is associated with NMDA-type glutamate receptor-dependent plasticity in the CeA and BNST. However, there is little evidence that NMDA receptors are expressed in CeA neurons projecting to the BNST, or are required for opioid-induced BNST neural activation. Immunoelectron microscopy, tract tracing, and conditional gene deletion technology were used to investigate the synaptic organization of the NMDA receptor and the mu-opioid receptor (μOR) in the CeA-BNST pathway. By dual labeling electron microscopy, numerous CeA-BNST projection neurons expressed the NMDA-NR1 receptor subunit (NR1) or μOR. By triple labeling, it was also found that NR1 and μOR were co-expressed in some CeA-BNST projection neurons. Despite being colocalized in somato-dendritic compartments of CeA neurons, NR1 and μOR were rarely expressed in their axonal terminations in the BNST. Deleting the NR1 gene in CeA neurons resulted in a reduction of morphine-induced Fos protein labeling in the ventral BNST. In summary, NR1 and μOR are coexpressed in somatodendritic sites of CeA neurons, including those projecting to the BNST. In addition, expression of the NR1 gene in CeA neurons is required for morphine-induced BNST neural activation. Thus, postsynaptic NMDA receptors and μORs are positioned for the co-modulation of CeA projection neurons to the BNST, which may provide a synaptic substrate for stress-induced emotional processes critically involved in opioid addictive behaviors.
Department of Neurology, Weill Cornell Medical College, New York, NY 10065, USA.
Marc A
MA
Beckerman
Michael J
MJ
Glass
D000679:Amygdala / Q000166:cytology*; D000701:Analgesics, Opioid / Q000494:pharmacology; D000818:Animals; D001710:Biotin / Q000031:analogs & derivatives / Q000378:metabolism; D003712:Dendrites / Q000378:metabolism* / Q000648:ultrastructure; D003911:Dextrans / Q000378:metabolism; D005786:Gene Expression Regulation / Q000187:drug effects / Q000235:genetics; D049452:Green Fluorescent Proteins / Q000378:metabolism; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D008822:Mice, Transgenic; D016253:Microscopy, Immunoelectron; D009020:Morphine / Q000494:pharmacology; D009434:Neural Pathways / Q000378:metabolism / Q000502:physiology; D009474:Neurons / Q000166:cytology*; D016194:Receptors, N-Methyl-D-Aspartate / Q000235:genetics / Q000378:metabolism*; D017450:Receptors, Opioid, mu / Q000378:metabolism*; D012686:Septal Nuclei / Q000502:physiology*; D013266:Stilbamidines / Q000378:metabolism; D013997:Time Factors
C049774:2-hydroxy-4,4'-diamidinostilbene, methanesulfonate salt; D000701:Analgesics, Opioid; D003911:Dextrans; C409466:NR1 NMDA receptor; D016194:Receptors, N-Methyl-D-Aspartate; D017450:Receptors, Opioid, mu; D013266:Stilbamidines; C076397:biotinylated dextran amine; D049452:Green Fluorescent Proteins; D001710:Biotin; D009020:Morphine